Feb 13, 2025 / 01:00PM GMT
Operator
Good morning. My name is Nadia, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines 4Q and FY 2024 earnings release and conference call.
(Operator Instructions)
Cassie Saitow, you may begin your conference.
Cassie Saitow - Blueprint Medicines Corp - Director, Investor Relations
Thank you, Nadia. Good morning, everyone, and welcome to Blueprint Medicine's fourth quarter 2024 financial and operating assaults conference call. This morning, we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as the slides we will be reviewing today by going to the investors section of our website at www.blueprintmedicines.com.
Joining me today are Kate Haviland, Chief Executive Officer; Philina Lee, Chief Commercial Officer; Becker Hewes, Chief Medical Officer; and Mike Landsittel, Chief Financial Officer; Fouad Namouni, President Research and
Q4 2024 Blueprint Medicines Corp Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
